ReCor's Renal Denervation System Gets Thumbs Up From FDA Advisory Panel
The panel voted overwhelmingly in favor of safety, but quibbled about efficacy, durability, and benefits versus risk.
Source: tctmd.com
Stay updated with breaking news from Continued Access Protocol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The panel voted overwhelmingly in favor of safety, but quibbled about efficacy, durability, and benefits versus risk.
/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...
TransMedics Group, Inc. (NASDAQ:TMDX) received premarket approval (PMA) from U.S. Food and Drug Administration (FDA) for its OCS™ Heart Syst...